Clinical Trial Update: A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCC [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating brivanib in Chinese patients with previously treated advanced hepatocellular carcinoma has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Brivanib (brivanib)

Snippet

Sponsor: Zai Lab (Shanghai) Co., Ltd. | Conditions: Hepatocellular Carcinoma (HCC) | Phase 2 | Status: COMPLETED